IPOH: Pharmaniaga Bhd plans to import 10 million doses of finished Sinovac Covid-19 vaccine from China, says its group managing director Datuk Zulkarnain Md Eusope.
KUALA LUMPUR: Pharmaniaga’s wholly-owned subsidiary, Pharmaniaga LifeScience Sdn Bhd (PLS), is ready to ramp up production from two million to four mi.
is on track to meet its contractual obligation to the Government ahead of the agreed delivery schedule by supplying both filled and finished as well as finished Sinovac Covid-19 vaccine.
In a statement Wednesday, the pharmaceutical company said it would be able to supply a total of 8.6 million doses by end June 2021.
“Pharmaniaga’s wholly-owned subsidiary Pharmaniaga LifeScience Sdn Bhd (PLS) is also ready to ramp up production from 2 million to 4 doses a month in order to help the Government expedite the vaccination programme and achieve herd immunity,” it said.
Group managing director Datuk Zulkarnain Md Eusope said up to May 23, PLS’s high-tech plant had completed fill and finish manufacturing a total of 1.88 million doses of Sinovac Covid-19 doses.
Wednesday, 26 May 2021 03:34 PM MYT
BY JERRY CHOONG
A man works in the packaging facility of Chinese vaccine maker Sinovac Biotech n Beijing September 24, 2020. Reuters pic
Subscribe to our Telegram channel for the latest updates on news you need to know.
KUALA LUMPUR, May 26 Concern that the approval of China’s Sinovac Covid-19 vaccine could lead to shortages has led domestic pharmaceutical corporation Pharmaniaga Berhad to announce it will import 10 million more doses.
Its managing director Datuk Zulkarnain Md Eusope said the company has taken into account the unpredictability of vaccine supplies, given current geopolitics and supply issues around the world.